SCHEMBL10050026

SCHEMBL10050026

COC(C)NC(=O)C(C)N1C(=O)C=CC1=O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 3/20 0.37
▸ HTT P42858 2/20 0.37
▸ ALOX15 P16050 1/20 0.37
▸ MAPK1 P28482 1/20 0.37
▸ POLB P06746 2/20 0.36
▸ ALDH1A1 P00352 5/20 0.35
▸ HSD17B10 Q99714 1/20 0.35
▸ L3MBTL1 Q9Y468 1/20 0.33
▸ CYP1A2 P05177 2/20 0.33
▸ CYP2C19 P33261 2/20 0.33
▸ HPGD P15428 1/20 0.33
▸ BLM P54132 1/20 0.33
▸ WRN Q14191 1/20 0.33
▸ HIF1A Q16665 1/20 0.33
▸ LMNA P02545 1/20 0.32
▸ KDM4E B2RXH2 2/20 0.32
▸ MEN1 O00255 1/20 0.32
▸ KMT2A Q03164 1/20 0.32
▸ NPSR1 Q6W5P4 1/20 0.32
▸ SLC1A2 P43004 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10310590 0.82 ALDH1A1 (0.37) SMN1; SMN2HTTALOX15MAPK1POLB
SCHEMBL327611 0.82 SMN1; SMN2 (0.35) SMN1; SMN2HTTALOX15MAPK1POLB
SCHEMBL12107536 0.82 CYP1A2 (0.43) SMN1; SMN2HTTALOX15MAPK1POLB
SCHEMBL10037551 0.79 POLB (0.38) SMN1; SMN2HTTALOX15MAPK1POLB
SCHEMBL13185397 0.77 POLB (0.37) SMN1; SMN2HTTALOX15MAPK1POLB
SCHEMBL10037571 0.77 POLB (0.37) SMN1; SMN2HTTALOX15MAPK1POLB
SCHEMBL12409956 0.76 POLB (0.35) SMN1; SMN2POLBALDH1A1L3MBTL1CYP1A2
SCHEMBL2610530 0.76 POLB (0.36) SMN1; SMN2HTTALOX15MAPK1POLB
SCHEMBL19543492 0.76 POLB (0.39) SMN1; SMN2HTTALOX15MAPK1POLB
SCHEMBL12109372 0.76 ALDH1A1 (0.39) SMN1; SMN2HTTALOX15MAPK1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8247536-B2 Factor VIII compositions NEKTAR THERAPEUTICS (US) 2012-08-21 — — US disclosed
US-8158746-B2 Active energy ray curable liquid composition and liquid cartridge CANON KABUSHIKI KAISHA (JP) 2012-04-17 — — US disclosed
US-20100324163-A1 ACTIVE ENERGY RAY CURABLE LIQUID COMPOSITION AND LIQUID CARTRIDGE CANON KABUSHIKI KAISHA (JP) 2010-12-23 — — US disclosed
US-20100120689-A1 POLYMER FACTOR VIII MOIETY CONJUGATES NEKTAR THERAPEUTICS (US) 2010-05-13 — — US disclosed
US-7579444-B2 Polymer-factor IX moiety conjugates NEKTAR THERAPEUTICS AL, CORPORATION (US) 2009-08-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100120689-A1 POLYMER FACTOR VIII MOIETY CONJUGATES F8, F9, F13B SMN1; SMN2 1435/4885HTT 2560/4885ALOX15 2864/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback